While many brain-computer interface companies are focused on helping paralyzed people communicate, Motif Neurotech is ...

Motif Neurotech, a brain-computer interface (BCI) company developing technologies for mental health, today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational ...

A large twin study found that adverse childhood experiences increase the risk of developing treatment-resistant depression.

Motif’s study primarily aims to validate the safety of its XCS system over a 12-month period following implantation.

This article is sponsored by Harper Clinic, a Utah-based clinic offering FDA-approved TMS therapy for treatment-resistant ...

Archaeologists and researchers at the ancient Roman site of Pompeii have used artificial intelligence for the first time to ...

A robot-assisted form of heat-sensitive moxibustion may offer a new, non-drug way to support people recovering from methamphetamine dependence while experiencing depressive symptoms.

“Think of it like charging your phone,” Motif co-founder and CEO Jacob Robinson told STAT’s O. Rose Broderick. Read their ...

Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from ...

Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced it has entered into ...

Detailed price information for Nexalin Technology Inc (NXL-Q) from The Globe and Mail including charting and trades.